What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?

Cancer Treatment Reviews

Volumn 39, Issue 4, 2013, Pages 366-374

  Calvo, Emiliano ^a   Ravaud, Alain ^b   Bellmunt, Joaquim ^c  

^a Centro Integral Oncológico Clara Campal and START Madrid   (Spain)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Anticancer therapy; Axitinib; Everolimus; Kidney cancer; Mechanism of action; Metastatic disease; Resistance; Sequential therapy

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYTOKINE; DOVITINIB; EVEROLIMUS; LINIFANIB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CARCINOMA; LYMPHOCYTE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT CODING; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84875553701     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.06.010     Document Type: Review

References (67)

1. Baldewijns M.M., van Vlodrop I., Vermeulen P.B., et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010, 221:125-138.
2. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12:122-127.
3. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
4. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
6. Rini B.I., Halabi S., Rosenberg J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
7. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
9. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
10. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
11. INLYTA® (axitinib) tablets for oral administration. New York, NY, USA: Pfizer Inc.; 2012.
12. Pfizer Inc. FDA Oncologic Drugs Advisory Committee Briefing Document (NDA 202324). Axitinib (AG-013736) for the treatment of patients with advanced renal cell carcinoma. Dec 7, 2011.; 2012 [accessed 01.02.12]. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm282284.htm.
13. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Kidney Cancer (version 2.2012). www.nccn.org; 2012 [accessed March 01.03.12].
15. Escudier B., Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v137-v139.
16. Ljungberg B., Cowan N.C., Hanbury D.C., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
17. de Reijke T.M., Bellmunt J., van Poppel H., Marreaud S., Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773.
18. Ravaud A., Gross-Goupil M. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat Rev 2012, 38:996-1003.
19. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 27:2278-2287.
20. Ebos J.M., Lee C.R., Cruz-Munoz W., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
21. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
22. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
23. Rini B., Escudier B., Tomkzac P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
24. Calvo E., Escudier B., Motzer R.J., et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2011, 48:333-339.
25. Gerullis H., Bergmann L., Maute L., et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010, 27:373-378.
26. Bergmann L., Kube U., Kindler M., et al. A noninterventional study of everolimus in metastatic renal cell cancer after use of 1 VEGFr-TKI: results of a preplanned interim analysis of a prospective study. J Clin Oncol 2011, 29(Suppl.). [abstr 4552].
27. Roca S., Quivy A., Gross-Goupil M., Bernhard J.C., De Clermont H., Ravaud A. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors. Acta Oncol 2011, 50:1135-1136.
28. Gruenwald V., Seidel C., Busch J., Fenner M., Weikert S. Second-line everolimus treatment is effective in RCC patients with poor progression-free survival (PFS) in first-line VEGF-targeted therapies. J Clin Oncol 2011, 29(Suppl.). [abstr e15028].
29. Weikert S., Kempkensteffen C., Busch J., et al. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J Urol 2011, [Epub ahead of print].
30. Grunwald V., Weikert S., Seidel C., et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie 2011, 34:310-314.
31. Mackenzie M.J., Rini B.I., Elson P., et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol 2011, 22:145-148.
32. Feinberg B.A., Jolly P., Wang S.T., et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 2011.
33. Wood L, Bukowski RN, Dreicer R, et al. Temsirolimus in metastatic RCC: safety and efficacy in patients previously treated with VEGF-targeted therapy. Presented at the 2008 ASCO Genitourinary Cancers Symposium; Feb 14-16, 2008; San Francisco, CA, USA; abstract 353.
34. Herrmann E., Marschner N., Grimm M.O., et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 2011, 29:361-366.
35. Porta C., Procopio G., Carteni G., et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011, 108:E250-E257.
36. Dudek A.Z., Zolnierek J., Dham A., Lindgren B.R., Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115:61-67.
37. Kontovinis L., Laschos K., Karadimou A., et al. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol 2011, [Epub ahead of print].
38. Tamaskar I., Garcia J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008, 179:81-86.
39. Eichelberg C., Heuer R., Chun F.K., et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008, 54:1373-1378.
40. Procopio G, Verzoni E, Guadalupi V, et al. Sequential use of sorafenib (So) followed by sunitinib (Su) in metastatic renal cell cancer (mRCC): a single-institution experience. Presented at the 2009 ASCO Genitourinary Cancers Symposium; Feb 26-28, 2009; Orlando, FL, USA; abstract 319.
41. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34.
42. Al-Marrawi M.Y., Rini B.I., Harshman R.C., et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). J Clin Oncol 2011, 29(Suppl.). [abstr 4555].
43. Richter S., Pfister D., Thuer D., Engelmann U.H., Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 2008, 31(Suppl. 4):234. [abstr V684].
44. Zimmermann K., Schmittel A., Steiner U., et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009, 76:350-354.
45. Di Lorenzo G., Carteni G., Autorino R., et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009, 27:4469-4474.
46. Garcia J.A., Hutson T.E., Elson P., et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010, 116:5383-5390.
47. Mancuso A.P., Donato De Paola E., Catalano A., et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. J Clin Oncol 2009, 27(Suppl.). [abstr e16027].
48. Rini B.I., Wilding G., Hudes G., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4462-4468.
49. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
50. Rini B.I., Escudier B.J., Michaelson M.D., et al. Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. J Clin Oncol 2012, 30(Suppl.). [abstr 354].
51. Bex A., Haanen J. Tilting the axis towards therapeutic limits in renal cancer. Lancet 2011, 378:1898-1900.
52. Rini B.I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
53. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011, 16(Suppl. 2):32-44.
54. Tsukamoto T., Shinohara N., Tsuchiya N., et al. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011, 41:17-24.
55. Tomita Y., Uemora H., Fujimoto H., et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a Japanese phase II study in patients with cytokine-refractory metastatic renal cell carcinoma (MRCC). Ann Oncol 2010, 21(Suppl. 8):viii282.
56. Cella D., Escudier B., Rini B.I., et al. Patient-reported outcomes in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma. J Clin Oncol 2011, 29(Suppl.). [abstr 4504].
57. Cella D., Escudier B., Rini B., et al. Time to deterioration (TDD) in patient-reported outcomes in phase 3 AXIS trial of axitinib vs sorenefib as second-line therapy for metastatic renal cell carcinoma (mRCC). Eur J Cancer 2011, 47(Suppl. 1). [abstr 3006].
58. Bracarda S., Escudier B., Porta C., et al. Randomized, placebo-controlled, phase 3 study of everolimus in patients with metastatic renal cell carcinoma (MRCC): subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy. Ann Oncol 2010, 21(Suppl. 8):viii292. [abstr 929P].
59. Schneider S.M., Hess K., Gosselin T. Interventions to promote adherence with oral agents. Semin Oncol Nurs 2011, 27:133-141.
60. Heng D.Y., Mackenzie M.J., Vaishampayan U.N., et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 2011, 10.1093/annonc/mdr533.
61. Busch J., Seidel C., Weikert S., et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer 2011, 11:295.
62. Albiges L., Lacovelli R., Porta C., et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib in metastatic renal cell carcinoma: is there any active treatment?. Eur J Cancer 2011, 47(Suppl. 1). [abstr 7143].
63. Hainsworth J.D., Spigel D.R., Burris H.A., et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010, 28:2131-2136.
64. Feldman D.R., Baum M.S., Ginsberg M.S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
65. Patel P.H., Senico P.L., Curiel R.E., Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009, 7:24-27.
66. Escudier B.J., Negrier S., Gravis G., et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 2010, 28(Suppl. 15). [abstr 4516].
67. Procopio G., Verzoni E., Iacovelli R., et al. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther 2011, 11:1631-1640.